Company: HURA
Filing Date: 2025-09-18
Form Type: S-1/A
Source: 0001193125-25-207395
Chunk: 213

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-09-18
Form: S-1/A
Chunk 213
---
 to purchase 181,134 shares of common stock required to be purchased in the Final Tranche Offering Amount on September 5, 2025 for an aggregate purchase price of $480,005.10 and the remaining 45,284 shares of the Final Tranche Offering Amount within five business days following the effectiveness of the registration statement of which this prospectus is a part in exchange for the Company’s agreement, set forth in the Warrant Amendment Agreement between the Company and Pranabio, to extend the expiration date of an aggregate of 694,888 of the 2024 Warrants. However, subsequent to the Final Purchase Agreement, and before the effectiveness of the registration statement of which this prospectus is a part, Pranabio and Garden Street did end up purchasing all of the shares in their respective Final Tranche Offering Amount. Under the Warrant Amendment Agreement, the expiration date of the 2024 Warrants was extended to December 31, 2030.136
**In addition, Matthew Nachtrab (“Nachtrab”), a beneficial owner of more than 5% of the TuHURA’s capital stock, entered into a Final Purchase Agreement with the Company whereby Nachtrab agreed to purchase 452,832 shares in his Final Tranche Offering Amount on September 5, 2025 for an aggregate purchase price of $1,200,004.80, and will purchase the remaining 113,208 shares in his Final Tranche Offering Amount (the “Remaining Shares”) on or before December 31, 2025 for an aggregate purchase price of $300,001.20, in exchange for the extension of the expiration date of an aggregate of 526,179 of the 2024 Warrants to December 31, 2030. Under Nachtrab’s Final Purchase Agreement, the Company and Nachtrab agreed that the Company will not be required to register for resale either (i) the 113,208 Remaining Shares or (ii) the 113,208 warrants to purchase shares of common stock to be issued at the time of the purchase of the Remaining Shares.

Warrant Exercise Promissory Notes

On February 12, 2025, KP Biotech Group, LLC and CA Patel F&F Investments, LLC (the “Makers”), holders of more than 5% of TuHURA’s capital stock and holder of certain common stock purchase warrants (the “Common Stock Warrants”), made and issued to TuHURA secured promissory notes (the